Document Detail


One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
MedLine Citation:
PMID:  20031786     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. METHODS AND RESULTS: The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients > or =45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or > or =3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were $2999, $2010, and $3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from $2401 to $3481. CONCLUSIONS: These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.
Authors:
Elizabeth M Mahoney; Kaijun Wang; David J Cohen; Alan T Hirsch; Mark J Alberts; Kim Eagle; Frederique Mosse; Joseph D Jackson; P Gabriel Steg; Deepak L Bhatt;
Related Documents :
10081636 - Is the presence of surgically treatable coronary artery disease a contraindication to l...
263836 - Pathology of the heart in kawasaki disease.
16446736 - Experimental models of arteriogenesis: differences and implications.
16779616 - Disturbed endothelial function of the internal thoracic artery in patients with coronar...
829536 - Echocardiographic recognition of ventricular septal aneurysm--a case report.
8345426 - Alveolar-arterial oxygen gradient in acute chest syndrome of sickle cell disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation. Cardiovascular quality and outcomes     Volume:  1     ISSN:  1941-7705     ISO Abbreviation:  Circ Cardiovasc Qual Outcomes     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2009-12-24     Completed Date:  2010-06-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101489148     Medline TA:  Circ Cardiovasc Qual Outcomes     Country:  United States    
Other Details:
Languages:  eng     Pagination:  38-45     Citation Subset:  IM    
Affiliation:
Saint Luke's Mid America Heart Institute, Kansas City, MO 64111, USA. emahoney1@saint-lukes.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Arteries / pathology
Atherosclerosis / drug therapy,  economics*,  pathology
Female
Follow-Up Studies
Health Care Costs / statistics & numerical data*
Humans
Male
Medical History Taking
Middle Aged
Monitoring, Ambulatory
Pharmaceutical Preparations / economics
Risk Factors
Thrombosis / drug therapy,  economics*,  pathology
Chemical
Reg. No./Substance:
0/Pharmaceutical Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An administrative claims measure suitable for profiling hospital performance on the basis of 30-day ...
Next Document:  Prevalence, awareness, treatment, and predictors of control of hypertension in new york city.